Accustem Sciences Inc.

OTC: ACUT · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001850767Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 20DQ —GM —SS 21

v0.1 · 35/100 weight · pillars only

↑ market scale, Altman-Z · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

$98.4k

Rev growth YoY (TTM)

+2610.7%

Net income (FY)

-$1.8M

Employees

as of 2026-08-24

Market cap

$2.6M

as of 2026-08-24

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$1.8M-$1.8M2025

Operating income-$1.8M-$1.8M2025

Total assets$1.5M$1.5M2025

Liabilities$5.0M$5.0M2025

Equity-$3.4M-$3.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Accustem Sciences Inc.’s financial profile?

Accustem Sciences Inc. earned -$1.8M in FY2025 net income.

Peers · Healthcare

Enzolytics Inc.——FibroBiologics, Inc. Common Stock——Strainsforpains, Inc.——Avricore Health Inc.——Clearmind Medicine Inc.——Endovia Health Sciences, Inc.——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOWendy E. Blosser

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeOTC: ACUT

Employees4

IPO date2022-03-03

Latest filings

10-Q2026-08-14 10-Q2026-05-15 10-K2026-04-14 8-K2025-11-26 10-Q2025-11-12 10-Q2025-08-14 10-Q2025-05-20 10-K2025-04-03

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.